Drug intelligence / Profile preview

Xinjingping

Development stage: Unknown

Overview

**Xinjingping** is an insufficiently characterized name that appears in a non-primary public dissertation listing for a treatment evaluated in coronary heart disease with heart failure and frequent premature ventricular contractions. Its active ingredient(s), dosage form, manufacturer, developer, pharmacology, and regulatory status could not be reliably established. The supplied CDE trial context instead identifies **Six Elements Electrolytes and Sodium Acetate Injection**, which cannot be verified as the same product as Xinjingping and is therefore not assigned to this record.

Other names: Xinjingping II

Beyond the preview

Go deeper on Xinjingping.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xinjingping.

Explore the full profile